脑部放疗，上午比下午敏感许多！
' D& ]6 @% U: }6 q6 c4 }# ~4 F. l/ c8 W% l F
1 r) a( Y6 L, U/ m) Y, tCancer 2011 Jan 15;117(2):414-20. doi: 10.1002/cncr.25423. Epub 2010 Sep 9.
+ }/ K2 ?7 d3 _; P: J& NGamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment?+ O7 v* `' p, V; P
Rahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM, Rich T.
8 B4 ~3 @' O5 j' J$ M7 d+ Y eSourceDepartment of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA.* [7 S4 Q' e& ~+ N h- m
7 e V! ] M4 ^% U6 c- Y# Q. IAbstract1 K# K# G, {4 S3 ~8 q) x
BACKGROUND: Circadian cell-cycle progression causes fluctuating radiosensitivity in many tissues, which could affect clinical outcomes. The purpose of this study was to determine whether outcomes of single-session gamma knife radiosurgery (GKRS) for metastatic nonsmall cell lung cancer (NSCLC) differ based on treatment time.
$ T7 b# t# i8 M9 r
/ v. @% @0 X7 E% F# x; wMETHODS: Fifty-eight patients received GKRS between 10:00 am and 12:30 pm and 39 patients received GKRS between 12:30 pm and 3:00 pm. The mean peripheral dose was 18.6 Gy. The mean tumor size was 7.3 cm³. Magnetic resonance imaging was used to score local control at 3 months. Cause of death (COD) was categorized as central nervous system (CNS)-related or systemic.2 L6 o2 k# `7 X* f2 z5 c6 W1 ^) D
: Q+ }1 {9 R0 n; a, X4 uRESULTS: Demographic and disease characteristics of the 2 groups were similar. Local control at 3 months was achieved in 97% (35/36) of patients who underwent GKRS early in the day versus 67% (8/12) of patients who underwent GKRS later in the day (chi-square, P = .014). Early GKRS was associated with better survival (median 9.5 months) than late GKRS (median 5 months) (Kaplan-Meier log-rank test, P = .025). Factors contributing to better survival in a Cox regression model included early treatment time (P = .004) and recursive partition analysis class (P < .001). Cause of death in the early treatment group was CNS-related in 6% (3/47) of patients versus 24% (8/34) of patients in the late treatment group (chi-square test, P = .026).
4 b/ a3 W$ M- a9 V" k4 p
) j* v+ N* C: G! n! X$ {CONCLUSIONS: GKRS for metastatic NSCLC had better local control, better survival, and a lower rate of CNS-related cause of death when given earlier in the day versus later in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.6 f( R2 M2 F) n' f! t7 b$ _
) A3 X4 I9 u1 Z% @8 `" W, G
|
权威开讲！仲佳教授详解小细胞肺癌治
作者：雨过天晴在肺癌家族中，小细胞肺癌虽仅占15%-20%的比例，却以“恶性程度高、进
重磅好消息！这三款肺癌靶向药进医保
12月7日，国家医保局公布最新医保目录，三款肺癌靶向药——氟泽雷塞、他雷替尼、塞普
EGFR19+C797S和MET扩增+1230C，奥西
250123
病人是我妈妈，43年8月的，81周岁。
19年10月28日确诊，肺腺癌晚期，右上肺
父亲确诊“癌王”生命危在旦夕，医护
讲述者：吉吉整理者：pear
一年前，父亲被确诊为胰腺癌伴肝转移，那一刻，我的人生仿
三代药泰瑞沙五年骨转，请教后续方案
17年右锁骨异常，穿刺确诊肺CA，基因检测19突变，无其他转移。服用易瑞沙，至2019肺部
) s+ }0 J5 N2 V
显身卡
